Literature DB >> 15753155

Vitamin E for the treatment of cardiovascular disease: is there a future?

Francesco Violi1, Roberto Cangemi, Giuseppe Sabatino, Pasquale Pignatelli.   

Abstract

Oxidative stress seems to play a key role in the pathogenesis of atherosclerosis. Agents that protect low-density lipoprotein from oxidation have been shown in a range of in vitro and animal models to reduce the development and progression of atherosclerosis. These agents include antioxidant micronutrients such as vitamin E. They have gained wide interest because of the potential for prevention of atherosclerotic vascular disease in humans. In the last decade, many trials with antioxidants have been carried out in patients with cardiovascular disease, but the results are equivocal. The reason for the disappointing findings is unclear, but one possible explanation is the lack of identification criteria of patients who are potential candidates for antioxidant treatment. This review analyses the data reported so far to determine whether they clearly support the premise that patients at risk of cardiovascular disease may be candidates for antioxidant treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15753155     DOI: 10.1196/annals.1331.029

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  3 in total

Review 1.  Botanical flavonoids on coronary heart disease.

Authors:  Chong-Zhi Wang; Sangeeta R Mehendale; Tyler Calway; Chun-Su Yuan
Journal:  Am J Chin Med       Date:  2011       Impact factor: 4.667

2.  Scavenger receptor class B type I (SR-BI) is involved in vitamin E transport across the enterocyte.

Authors:  Emmanuelle Reboul; Alexis Klein; Florence Bietrix; Béatrice Gleize; Christiane Malezet-Desmoulins; Martina Schneider; Alain Margotat; Laurent Lagrost; Xavier Collet; Patrick Borel
Journal:  J Biol Chem       Date:  2005-12-27       Impact factor: 5.157

3.  Dietary supplementation with vitamin E ameliorates cardiac failure in type I diabetic cardiomyopathy by suppressing myocardial generation of 8-iso-prostaglandin F2alpha and oxidized glutathione.

Authors:  Milton Hamblin; Holly M Smith; Michael F Hill
Journal:  J Card Fail       Date:  2007-12       Impact factor: 5.712

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.